Efficacy and Safety of Ciclesonide, 200 Microg Once Daily, for the Treatment of Perennial Allergic Rhinitis
Overview
Pulmonary Medicine
Authors
Affiliations
Background: Ciclesonide is an intranasal corticosteroid approved for the treatment of allergic rhinitis (AR).
Objective: To evaluate the efficacy, safety, and quality-of-life benefits of intranasal ciclesonide, 200 microg once daily, for the treatment of perennial AR (PAR).
Methods: In this multicenter, randomized, double-blind, placebo-controlled study, adults and adolescents with at least a 2-year history of PAR received intranasal ciclesonide, 200 microg, or placebo once daily for 6 weeks. Patient-evaluated total nasal symptom scores (TNSSs), physician-assessed overall nasal signs and symptoms severity scores, and Rhinoconjunctivitis Quality of Life Questionnaire scores were evaluated.
Results: Patient baseline characteristics were similar in the ciclesonide (n = 238) and placebo (n = 233) groups and were consistent with moderate PAR severity. Ciclesonide therapy significantly reduced average morning and evening reflective TNSSs compared with placebo (P < .001) and significantly reduced average morning and evening instantaneous TNSSs (P = .001) over 6 weeks of treatment. At the end point, a greater decrease from baseline was observed in physician-assessed overall nasal signs and symptoms severity for the ciclesonide group compared with the placebo group (P = .051). An appreciable improvement in combined Rhinoconjunctivitis Quality of Life Questionnaire scores at the end point was also observed in the ciclesonide group (P = .01 vs placebo). The frequency of adverse events was similar between treatment groups.
Conclusions: In this study, intranasal ciclesonide treatment was associated with significant reductions in nasal symptoms and appreciable improvements in health-related quality of life in adult and adolescent patients with PAR. Ciclesonide was well tolerated, with a safety profile comparable with that of placebo.
Efficacy of and (NVP-1703) in Children With Allergic Rhinitis: A Randomized Controlled Trial.
Jeong K, Jang S, Jeon S, Seo H, Kang S, Han S J Korean Med Sci. 2024; 39(40):e266.
PMID: 39435516 PMC: 11496560. DOI: 10.3346/jkms.2024.39.e266.
Soe K, Krikeerati T, Pheerapanyawaranun C, Niyomnaitham S, Phinyo P, Thongngarm T Front Pharmacol. 2023; 14:1184552.
PMID: 37288109 PMC: 10242043. DOI: 10.3389/fphar.2023.1184552.
Yang Q, Wang F, Li B, Wu W, Xie D, He L Braz J Otorhinolaryngol. 2018; 85(3):371-378.
PMID: 30522830 PMC: 9442893. DOI: 10.1016/j.bjorl.2018.10.008.
The burden of allergic rhinitis (AR) in Canada: perspectives of physicians and patients.
Keith P, Desrosiers M, Laister T, Schellenberg R, Waserman S Allergy Asthma Clin Immunol. 2012; 8(1):7.
PMID: 22656186 PMC: 3490734. DOI: 10.1186/1710-1492-8-7.
Intranasal ciclesonide for allergic rhinitis.
Williams B, Smith W, Kette F J Asthma Allergy. 2011; 1:49-54.
PMID: 21436985 PMC: 3121337. DOI: 10.2147/jaa.s3082.